Noninvasive Detection of Hepatocellular Carcinoma with Circulating Tumor DNA Features and α-Fetoprotein

Meng, Zuowei; Ren, Qingqi; Zhong, Guolin; Li, Shiyong; Chen, Yan; Wu, Wei; Feng, Yukuan; Mao, Mao; zhang, Feng; Long, Guanghui

doi:10.1016/j.jmoldx.2021.06.003

Cited by 17 publications

(24 citation statements)

References 36 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At chromosomal level, 1q and 8q amplifications are detected frequently, while the deletion of 1p, 4q, and 8p also typically are observed ( Figure 1 B ). 22 , 29 , 30 , 31 , 32 , 33 As for the gene level, amplification of CDK6, epidermal growth factor receptor ( EGFR ) , MYC proto-oncogene, bHLH transcription factor ( MYC ) , BRAF , and CCNE1 are reported frequently, whereas deletion events are less consistent among studies. 11 , 13 , 15 , 25 The earlier-described chromosomes and genes are the common and conserved CNV signatures possessed by HCC patients and readily revealed by the CNV landscape obtained from patients’ cfDNA.…”

Section: Molecular Landscapes Of Ctdna In Hccmentioning

confidence: 99%

See 1 more Smart Citation

Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma

Lyu

Tsui

et al. 2022

Cellular and Molecular Gastroenterology and Hepatology

View full text Add to dashboard Cite

Section: Molecular Landscapes Of Ctdna In Hccmentioning

confidence: 99%

“… 49 Plasma cfDNA CNV discovered by shallow whole-genome sequencing, when combined with fragment size and AFP, facilitates early detection of HCC by achieving 92.6% accuracy and better performance than other predictors. 32 …”

Section: Use Of Cfdna In the Clinical Management Of Hccmentioning

confidence: 99%

Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma

Lyu

Tsui

et al. 2022

Cellular and Molecular Gastroenterology and Hepatology

View full text Add to dashboard Cite

“…(1) Patients with previous treatment history; (2) Patients with other malignant tumors. In the prospective study, we collected blood samples from HCC patients who received SBRT from December 2017 to December 2018.…”

Section: Patient Selection and Medical Record Collectionmentioning

confidence: 99%

“… 1 Hepatocellular carcinoma (HCC) is the leading pathologic subtype contributing 85–90% of primary liver cancer. 2 The main risk factors for liver cancer are chronic hepatitis B virus HBV or hepatitis C virus HCV, heavy alcohol intake, aflatoxin-contaminated foods, obesity, smoking, etc. Among all cancers in China, liver cancer has the poorest survival except for pancreatic cancer and the age-standardized 5-year relative survival is only 14.1%.…”

Section: Introductionmentioning

confidence: 99%

Screening of Prognostic Biomarkers for Stereotactic Body Radiation Therapy in Primary Liver Cancer

et al. 2022

View full text Add to dashboard Cite

Objective So far there are still no effective immediate-early markers for assessing the efficacy of Stereotactic Body Radiation Therapy (SBRT). To find effective biomarkers for accurate assessment of the efficacy of SBRT in patients with primary liver cancer, we conducted this study including retrospective part and prospective part. Material and Methods 589 patients with primary liver cancer were included at Ruikang Hospital affiliated to Guangxi Medical University from January 2012 to December 2018. Follow-up was conducted, clinical information and a total of 17 patients with 51 blood samples (before SBRT, before discharge and 2 months after SBRT) were collected. mRNAs profiles on 2 patients with 6 blood samples were detected by high-throughput sequencing, followed by qPCR verification on 15 patients with 45 blood samples. Results The commonly used serum biomarkers such as AFP, CEA, and CA125 shown low prognostic value in distinguishing survival group and death group, indicated by low AUC (less than .7) and Youden indexes (less than .5). Based on high-throughput sequencing of test group and qPCR detection of another verification group, we found 16 up-regulated and 12 downregulated genes after SBRT. Among them, ADIPOR1 and EPB42 showed significantly different between effective and ineffective group after SBRT, ROC suggested that based on the optimal threshold of .5838, ADIPOR1 shown a sensitivity of 100% and a specificity of 83.33% to distinguish effective from ineffective group. And EPB42 had a sensitivity of 75% and a specificity of 100% at the optimal threshold of 1.3817. In addition, GSEA showed that high expression of ADIPOR1 was mainly related to Mismatch repair, Circadian rhythm, Protein processing in endoplasmic reticulum, DNA replication, and Fanconi anemia pathways. Conclusion ADIPOR1 in whole blood is a promising candidate to act as prognostic biomarker for predication of SBRT outcomes in primary liver cancer patients.

show abstract

“…According to the World Health Organization, the number of deaths from liver cancer will exceed 1 million by 2030, thus posing a major threat to human health 3 . The 2 most frequent forms of liver cancer are hepatocellular carcinoma (HCC) and cholangiocarcinoma, which represent 85%–90% and 6%–15% of all primary liver cancers, respectively 4 , 5 .…”

Section: Introductionmentioning

confidence: 99%

The advanced development of molecular targeted therapy for hepatocellular carcinoma

Yan

Zhang

et al. 2022

Cancer Biol Med

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC), one of the most common malignant tumors in China, severely threatens the life and health of patients. In recent years, precision medicine, clinical diagnoses, treatments, and innovative research have led to important breakthroughs in HCC care. The discovery of new biomarkers and the promotion of liquid biopsy technologies have greatly facilitated the early diagnosis and treatment of HCC. Progress in targeted therapy and immunotherapy has provided more choices for precise HCC treatment. Multiomics technologies, such as genomics, transcriptomics, and metabolomics, have enabled deeper understanding of the occurrence and development mechanisms, heterogeneity, and genetic mutation characteristics of HCC. The continued promotion and accurate typing of HCC, accurate guidance of treatment, and accurate prognostication have provided more treatment opportunities and prolonged survival timelines for patients with HCC. Innovative HCC research providing an in-depth understanding of the biological characteristics of HCC will be translated into accurate clinical practices for the diagnosis and treatment of HCC.

show abstract

Noninvasive Detection of Hepatocellular Carcinoma with Circulating Tumor DNA Features and α-Fetoprotein

Cited by 17 publications

References 36 publications

Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma

Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma

Screening of Prognostic Biomarkers for Stereotactic Body Radiation Therapy in Primary Liver Cancer

The advanced development of molecular targeted therapy for hepatocellular carcinoma

Contact Info

Product

Resources

About